Design of a transdermal delivery system for aspirin as an antithrombotic drug

International Journal of Pharmaceutics

Volumn 327, Issue 1-2, 2006, Pages 81-88

  Ammar, H O ^a   Ghorab, M ^b   El Nahhas, S A ^a   Kamel, R ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Aspirin; Cardiovascular diseases; Platelet aggregation inhibition; Transdermal

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACETYLSALICYLIC ACID; ALCOHOL; ANTICOAGULANT AGENT; BETA CYCLODEXTRIN; CYCLODEXTRIN; ESTER; FATTY ACID; GLYCOL; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; HYDROCARBON; LIMONENE; OLEIC ACID; PROPYLENE GLYCOL; TERPENE; UREA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; FEASIBILITY STUDY; GEL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ASPIRIN; CARBOXYMETHYLCELLULOSE; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DIMETHYL SULFOXIDE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; FATTY ALCOHOLS; FIBRINOLYTIC AGENTS; MALE; MINERAL OIL; MYRISTATES; PETROLATUM; PLATELET AGGREGATION; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SKIN ABSORPTION; SODIUM DODECYL SULFATE; UREA;

EID: 33750511934     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.07.054     Document Type: Article

References (31)

1. Ammar H.O., Salama H.A., Ghorab M., El-Nahhas S., and Elmotasem H. A transdermal delivery system for glipizide. Curr. Drug Deliv. 3 (2006) 333-341
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 328 (2002) 71-86
3. Arellano A., Santoyo S., Martin C., and Ygartua P. Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels. Eur. J. Pharm. Sci. 7 (1999) 129-135
4. Bendas B., Schmalfuss U., and Neubert R. Influence of propylene glycol as cosolvent on mechanisms of drug transport from hydrogels. Int. J. Pharm. 116 (1995) 19-30
5. Block, L.H., 1995. Medicated applications. In: Gennaro, A.R. (Ed.), Remington, pp. 1577-1591.
6. Cardinal D.C., and Flower R.J. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J. Pharmacol. Methods 3 (1980) 155-158
7. De La Cruz J.P., Gonzalez-Correa J.A., Guerrero A., Marquez E., Martos F., and Sanchez de la cuesta F. Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers. Fund. Clin. Pharm. 17 (2003) 363-372
8. Desai A.A., Nakay V.K., Desai N.K., and Gupta K.C. Effect of nifedipine and aspirin on platelet aggregation: a study in hypertensive patients and normal volunteers. Ind. J. Pharm. 27 (1995) 167-170
9. Embil K., and Torosian G. Dissolution behavior of commercial enteric-coated aspirin tablets. J. Pharm. Sci. 68 (1979) 1290-1292
10. Friggeri A., Feringa B.L., and van Esch J. Entrapment and release of quinoline derivatives using a hydrogel of a low molecular weight gelator. J. Control. Rel. 97 (2004) 241-248
11. Keimowitz R.M., Pulvermacher G., Mayo G., and Fitzgerald D.J. Transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 88 (1993) 556-561
12. Keimowitz R.M. Transdermal aspirin and gastric ulcer healing after coronary artery stent placement. Circulation 94 (1996) 3002
13. Krishna D.R., Srinivas A.G., and Srinivas A. Transdermal aspirin: influence of platelet aggregation and lipid peroxides. Ind. J. Pharm. Sci. 63 (2000) 200-204
14. Laffan M.A., and Manning R.A. Investigation of homeostasis. In: Levis S.M., Bain B.J., and Bates I. (Eds). Practical Hematology (2001) 339-390
15. Loftsson T., and Olafsson J.H. Cyclodextrins: new drug delivery systems in dermatology. Int. J. Dermatol. 37 (1998) 241-246
16. 2 synthase. Nat. Struct. Biol. 2 (1995) 637-643
17. Malhotra S., Sharma Y.P., Grover A., Majumdar S., Hanif S.M., Bhargava V.K., Bhatnagar A., and Pandhi P. Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern. Med. J. 33 (2003) 350-354
18. Mizobuchi, N., Hasegawa, Y., Kawada, M., Hisaichi, S., 2001. Stable aspirin-containing preparations for external use. US Patent 6,268,355.
19. Morimoto H., Wada Y., Seki T., and Sugibayashi K. In vitro skin permeation of morphine hydrochloride during the finite application of penetration-enhancing system containing water, ethanol and l-menthol. Biol. Pharm. Bull. 25 (2002) 134-136
20. Patrono C., Collar B., Dalen J., Fuster V., Gent M., Harker L., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness and side-effects. Chest 114 (1998) 470S-488S
21. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 330 (1994) 1287-1294
22. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am. J. Med. 110 (2001) 62S-65S
23. Pedersen A.K., and Fitzgerald G.A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311 (1984) 1206-1211
24. Pershing L.K., Lambert L.D., and Knutson K. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. Pharm. Res. 7 (1990) 762-766
25. Roth G.J., Stanford N., and Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U.S.A. 72 (1975) 3073-3077
26. Schror K. Antiplatelets drugs. A comparative review. Drugs 50 (1995) 7-28
27. Tupker R.A., Pinnagoda J.P., and Nater J.P. The transient and cumulative effect of sodium lauryl sulphate on the epidermal barrier assessed by transepidermal water loss: inter-individual variation. Acta Derm. Venereol. 70 (1990) 1-5
28. The Dutch TIA Trial Study Group. A comparaison of two doses of aspirin in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325 (1991) 1261-1266
29. Victoria M., Bentley B., Renata F., Wilson S., and Collett J.H. Caracterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol. 49 (1997) 397-402
30. Weksler B.B., Pett S.B., Alonso D., Richter R.C., Stelzer P., Subramanian V., Track-Goldman K., and Gay W.A. N. Engl. J. Med. 308 (1983) 800-805
31. Williams A.C., and Barry B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 56 (2004) 603-618